Download PDF
Semin Neurol 2019; 39(06): 749-760
DOI: 10.1055/s-0039-1700527
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Update on Ocular Myasthenia Gravis

Meabh O'Hare
1   Department of Neurology, Brigham & Women's Hospital, Boston
,
Christopher Doughty
1   Department of Neurology, Brigham & Women's Hospital, Boston
› Author Affiliations
Further Information

Publication History

Publication Date:
17 December 2019 (online)

    Permissions and Reprints

Abstract

Myasthenia gravis is an antibody-mediated autoimmune disorder of the post-synaptic neuromuscular junction resulting in fluctuating, fatigable weakness. Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]). The history and clinical examination are of the utmost importance in correctly identifying OMG patients, as supportive serologic or electrodiagnostic studies are frequently nondiagnostic. In this review, we outline a diagnostic approach to OMG (focusing on key clinical features), discuss therapeutic options, and highlight recent developments in the understanding of OMG.

Keywords

ocular myasthenia gravis - ptosis - diplopia - neuromuscular junction - acetylcholine receptor antibody
 

  • References

  • 1 Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis 2012; 2012: 874680
    PubMedGoogle Scholar
  • 2 Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37 (02) 141-149
    CrossrefPubMedGoogle Scholar
  • 3 Bever Jr. CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14 (05) 516-519
    CrossrefPubMedGoogle Scholar
  • 4 Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77 (01) 31-35
    CrossrefPubMedGoogle Scholar
  • 5 Jaretzki III A, Barohn RJ, Ernstoff RM. , et al; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000; 55 (01) 16-23
    CrossrefPubMedGoogle Scholar
  • 6 Ruff RL, Lisak RP. Nature and action of antibodies in myasthenia gravis. Neurol Clin 2018; 36 (02) 275-291
    CrossrefPubMedGoogle Scholar
  • 7 Thanvi BR, Lo TCN. Update on myasthenia gravis. Postgrad Med J 2004; 80 (950) 690-700
    CrossrefPubMedGoogle Scholar
  • 8 Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014; 52: 90-100
    CrossrefPubMedGoogle Scholar
  • 9 Sommer N, Tackenberg B, Hohlfeld R. Chapter 5 The immunopathogenesis of myasthenia gravis. In: Engel AG. , ed. Handbook of Clinical Neurology. New York, NY: Elsevier; 2008: 169-212
    Google Scholar
  • 10 Mori S, Kubo S, Akiyoshi T. , et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012; 180 (02) 798-810 [published Online First: 2011/12/07]
    CrossrefPubMedGoogle Scholar
  • 11 Shen C, Lu Y, Zhang B. , et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 2013; 123 (12) 5190-5202
    CrossrefPubMedGoogle Scholar
  • 12 Rodríguez Cruz PM, Al-Hajjar M, Huda S. , et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol 2015; 72 (06) 642-649
    CrossrefPubMedGoogle Scholar
  • 13 Jacob S, Viegas S, Leite MI. , et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012; 69 (08) 994-1001
    PubMedGoogle Scholar
  • 14 Cortés-Vicente E, Gallardo E, Martínez MÁ. , et al. Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 2016; 73 (09) 1099-1104
    CrossrefPubMedGoogle Scholar
  • 15 Gallardo E, Martínez-Hernández E, Titulaer MJ. , et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014; 13 (10) 1003-1007
    CrossrefPubMedGoogle Scholar
  • 16 Marx A, Müller-Hermelink HK, Ströbel P. The role of thymomas in the development of myasthenia gravis. Ann N Y Acad Sci 2003; 998 (01) 223-236
    CrossrefPubMedGoogle Scholar
  • 17 Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013; 12 (09) 875-884
    CrossrefPubMedGoogle Scholar
  • 18 Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000; 247 (05) 369-375
    CrossrefPubMedGoogle Scholar
  • 19 Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci 2003; 998: 362-374
    CrossrefPubMedGoogle Scholar
  • 20 Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis?. Neurology 1990; 40 (11) 1663-1669
    CrossrefPubMedGoogle Scholar
  • 21 Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010; 10: 46-46 . Doi: 10.1186/1471-2377-10-46
    CrossrefPubMedGoogle Scholar
  • 22 Peragallo JH, Bitrian E, Kupersmith MJ. , et al. Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuroophthalmol 2016; 36 (01) 29-32
    CrossrefPubMedGoogle Scholar
  • 23 Kee HJ, Yang HK, Hwang J-M. , et al. Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in asians. Neuromuscul Disord 2019; 29 (04) 296-301
    CrossrefPubMedGoogle Scholar
  • 24 Osher RH, Glaser JS. Myasthenic sustained gaze fatigue. Am J Ophthalmol 1980; 89 (03) 443-445
    CrossrefPubMedGoogle Scholar
  • 25 Pourmand R. Myasthenia gravis. Dis Mon 1997; 43 (02) 65-109
    PubMedGoogle Scholar
  • 26 Averbuch-Heller L, Poonyathalang A, von Maydell RD, Remler BF. Hering's law for eyelids: still valid. Neurology 1995; 45 (09) 1781-1783
    PubMedGoogle Scholar
  • 27 Pelak VS, Galetta SL. Ocular myasthenia gravis. Curr Treat Options Neurol 2001; 3 (04) 367-376
    CrossrefPubMedGoogle Scholar
  • 28 Osher RH, Griggs RC. Orbicularis fatigue: the ‘peek’ sign of myasthenia gravis. Arch Ophthalmol 1979; 97 (04) 677-679
    CrossrefPubMedGoogle Scholar
  • 29 Lepore FE, Sanborn GE, Slevin JT. Pupillary dysfunction in myasthenia gravis. Ann Neurol 1979; 6 (01) 29-33
    CrossrefPubMedGoogle Scholar
  • 30 Yamazaki A, Ishikawa S. Abnormal pupillary responses in myasthenia gravis. A pupillographic study. Br J Ophthalmol 1976; 60 (08) 575-580
    CrossrefPubMedGoogle Scholar
  • 31 Dutton GN, Garson JA, Richardson RB. Pupillary fatigue in myasthenia gravis. Trans Ophthalmol Soc U K 1982; 102 (Pt 4): 510-513
    PubMedGoogle Scholar
  • 32 Cooper J, Pollak GJ, Ciuffreda KJ, Kruger P, Feldman J. Accommodative and vergence findings in ocular myasthenia: a case analysis. J Neuroophthalmol 2000; 20 (01) 5-11
    CrossrefPubMedGoogle Scholar
  • 33 Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists' management guidelines. Pract Neurol 2015; 15 (03) 199-206
    CrossrefPubMedGoogle Scholar
  • 34 Andonopoulos AP, Terzis E, Tsibri E, Papasteriades CA, Papapetropoulos T. D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?. Clin Rheumatol 1994; 13 (04) 586-588
    CrossrefPubMedGoogle Scholar
  • 35 Drosos AA, Christou L, Galanopoulou V, Tzioufas AG, Tsiakou EK. D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol 1993; 11 (04) 387-391
    PubMedGoogle Scholar
  • 36 Suzuki S, Ishikawa N, Konoeda F. , et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017; 89 (11) 1127-1134
    CrossrefPubMedGoogle Scholar
  • 37 Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 2018; 18 (10) 63
    CrossrefPubMedGoogle Scholar
  • 38 Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017; 82: 128-136
    CrossrefPubMedGoogle Scholar
  • 39 Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy. J Neuromuscul Dis 2017; 4 (02) 169-173
    PubMedGoogle Scholar
  • 40 Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016; 54 (01) 157-161
    CrossrefPubMedGoogle Scholar
  • 41 Shah M, Tayar JH, Adbel-Wahab N, Suarez-Almazore ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2018; 48 (04) 736-740
    PubMedGoogle Scholar
  • 42 Brahmer JR, Lacchetti C, Schneider BJ. , et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36 (17) 1714-1768
    CrossrefPubMedGoogle Scholar
  • 43 Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987; 37 (08) 1383-1385
    CrossrefPubMedGoogle Scholar
  • 44 Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC. The ice test versus the rest test in myasthenia gravis. Ophthalmology 2000; 107 (11) 1995-1998
    CrossrefPubMedGoogle Scholar
  • 45 Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006; 16 (07) 459-467
    CrossrefPubMedGoogle Scholar
  • 46 Fakiri MO, Tavy DL, Hama-Amin AD, Wirtz PW. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve 2013; 48 (06) 902-904
    CrossrefPubMedGoogle Scholar
  • 47 Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to Tensilon. J Clin Neuroophthalmol 1991; 11 (04) 288-292
    PubMedGoogle Scholar
  • 48 Cogan DG. Myasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign. Arch Ophthalmol 1965; 74: 217-221
    CrossrefPubMedGoogle Scholar
  • 49 Van Stavern GP, Bhatt A, Haviland J, Black EH. A prospective study assessing the utility of Cogan's lid twitch sign in patients with isolated unilateral or bilateral ptosis. J Neurol Sci 2007; 256 (1,2): 84-85
    CrossrefPubMedGoogle Scholar
  • 50 Moorthy G, Behrens MM, Drachman DB. , et al. Ocular pseudomyasthenia or ocular myasthenia ‘plus’: a warning to clinicians. Neurology 1989; 39 (09) 1150-1154
    CrossrefPubMedGoogle Scholar
  • 51 Ragge NK, Hoyt WF. Midbrain myasthenia: fatigable ptosis, ‘lid twitch’ sign, and ophthalmoparesis from a dorsal midbrain glioma. Neurology 1992; 42 (04) 917-919
    CrossrefPubMedGoogle Scholar
  • 52 Apinyawasisuk S, Zhou X, Tian JJ, Garcia GA, Karanjia R, Sadun AA. Validity of forced eyelid closure test: a novel clinical screening test for ocular myasthenia gravis. J Neuroophthalmol 2017; 37 (03) 253-257
    CrossrefPubMedGoogle Scholar
  • 53 Howard Jr FM, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 526-538
    CrossrefPubMedGoogle Scholar
  • 54 Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84 (04) 309-333
    CrossrefPubMedGoogle Scholar
  • 55 Vaphiades MS, Bhatti MT, Lesser RL. Ocular myasthenia gravis. Curr Opin Ophthalmol 2012; 23 (06) 537-542
    CrossrefPubMedGoogle Scholar
  • 56 Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg 2018; 118 (03) 435-443
    CrossrefPubMedGoogle Scholar
  • 57 Benatar M, Mcdermott MP, Sanders DB. , et al; Muscle Study Group (MSG). Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle Nerve 2016; 53 (03) 363-369
    CrossrefPubMedGoogle Scholar
  • 58 Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E. Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry 2017; 88 (09) 761-763
    CrossrefPubMedGoogle Scholar
  • 59 Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71 (17) 1335-1341
    CrossrefPubMedGoogle Scholar
  • 60 Sanders DB, Andrews PI, Howard JF, Massey JM. Seronegative myasthenia gravis. Neurology 1997; 48 (Suppl. 05) 40S-45S
    CrossrefPubMedGoogle Scholar
  • 61 McConville J, Farrugia ME, Beeson D. , et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55 (04) 580-584
    CrossrefPubMedGoogle Scholar
  • 62 Evoli A, Tonali PA, Padua L. , et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126 (Pt 10): 2304-2311
    CrossrefPubMedGoogle Scholar
  • 63 Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44 (01) 36-40
    CrossrefPubMedGoogle Scholar
  • 64 Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60 (12) 1978-1980
    CrossrefPubMedGoogle Scholar
  • 65 Zisimopoulou P, Evangelakou P, Tzartos J. , et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014; 52: 139-145
    CrossrefPubMedGoogle Scholar
  • 66 Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69 (02) 418-422
    CrossrefPubMedGoogle Scholar
  • 67 Zhang B, Tzartos JS, Belimezi M. , et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69 (04) 445-451
    CrossrefPubMedGoogle Scholar
  • 68 Pevzner A, Schoser B, Peters K. , et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259 (03) 427-435
    CrossrefPubMedGoogle Scholar
  • 69 Tzartos JS, Zisimopoulou P, Rentzos M. , et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 2014; 1 (02) 80-87
    CrossrefPubMedGoogle Scholar
  • 70 Rivner MH, Liu S, Quarles B. , et al. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve 2017; 55 (03) 430-432
    CrossrefPubMedGoogle Scholar
  • 71 Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004; 24 (01) 31-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Seybold ME. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43 (08) 842-843
    CrossrefPubMedGoogle Scholar
  • 73 Dirr LY, Donofrio PD, Patton JF, Troost BT. A false-positive edrophonium test in a patient with a brainstem glioma. Neurology 1989; 39 (06) 865-867
    CrossrefPubMedGoogle Scholar
  • 74 Fierro B, Croce G, Filosto L, Carbone N, Lupo I. Ocular pseudomyasthenia: report of a case with a pineal region tumor. Ital J Neurol Sci 1991; 12 (06) 593-596
    CrossrefPubMedGoogle Scholar
  • 75 AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001; 24 (09) 1236-1238
    CrossrefPubMedGoogle Scholar
  • 76 Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. 3rd ed. New York, NY: Saunders; 2012
    Google Scholar
  • 77 Howard Jr JF. Electrodiagnosis of disorders of neuromuscular transmission. Phys Med Rehabil Clin N Am 2013; 24 (01) 169-192
    CrossrefPubMedGoogle Scholar
  • 78 Zambelis T, Kokotis P, Karandreas N. Repetitive nerve stimulation of facial and hypothenar muscles: relative sensitivity in different myasthenia gravis subgroups. Eur Neurol 2011; 65 (04) 203-207
    CrossrefPubMedGoogle Scholar
  • 79 Sanders DB, Howard Jr JF. AAEE minimonograph #25: Single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9 (09) 809-819
    CrossrefPubMedGoogle Scholar
  • 80 Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol 2014; 125 (06) 1270-1273
    CrossrefPubMedGoogle Scholar
  • 81 Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48 (12) 1246-1252
    CrossrefPubMedGoogle Scholar
  • 82 Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol 2014; 69 (05) e230-e245
    CrossrefPubMedGoogle Scholar
  • 83 Sommer N, Sigg B, Melms A. , et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62 (02) 156-162
    CrossrefPubMedGoogle Scholar
  • 84 Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505: 472-499
    CrossrefPubMedGoogle Scholar
  • 85 Gilhus NE. Myasthenia Gravis. N Engl J Med 2016; 375 (26) 2570-2581
    CrossrefPubMedGoogle Scholar
  • 86 Mazzoli M, Ariatti A, Valzania F. , et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 2018; 128 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 87 Wong SH, Petrie A, Plant GT. Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 2016; 36 (03) 252-258
    CrossrefPubMedGoogle Scholar
  • 88 Weinberg DH, Rizzo III JF, Hayes MT, Kneeland MD, Kelly Jr JJ. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999; 22 (09) 1222-1227
    CrossrefPubMedGoogle Scholar
  • 89 Rostedt A, Saders LL, Edards LJ, Massey JM, Sanders DB, Stålberg EV. Predictive value of single-fiber electromyography in the extensor digitorum communis muscle of patients with ocular myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis 2000; 2 (01) 6-9
    CrossrefPubMedGoogle Scholar
  • 90 Guan YZ, Cui LY, Liu MS, Niu JW. Single-fiber electromyography in the extensor digitorum communis for the predictive prognosis of ocular myasthenia gravis: a retrospective study of 102 cases. Chin Med J (Engl) 2015; 128 (20) 2783-2786
    CrossrefPubMedGoogle Scholar
  • 91 Suzuki S, Murai H, Imai T. , et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurol 2014; 14 (01) 142
    CrossrefPubMedGoogle Scholar
  • 92 Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009; 256 (08) 1314-1320
    CrossrefPubMedGoogle Scholar
  • 93 Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23 (04) 251-255
    CrossrefPubMedGoogle Scholar
  • 94 Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217 (02) 131-133
    CrossrefPubMedGoogle Scholar
  • 95 Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996; 53 (08) 802-804
    CrossrefPubMedGoogle Scholar
  • 96 Europa TA, Nel M, Heckmann JM. Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies. Muscle Nerve 2018; 58 (04) 542-549
    CrossrefPubMedGoogle Scholar
  • 97 Guidon AC, Hobson-Webb LD. On the double: early immunotherapy speeds recovery of ocular myasthenic weakness. Muscle Nerve 2018; 58 (06) 743-744
    CrossrefPubMedGoogle Scholar
  • 98 Haines SR, Thurtell MJ. Treatment of ocular myasthenia gravis. Curr Treat Options Neurol 2012; 14 (01) 103-112
    CrossrefPubMedGoogle Scholar
  • 99 Morris OC, O'Day J. Strabismus surgery in the management of diplopia caused by myasthenia gravis. Br J Ophthalmol 2004; 88 (06) 832
    PubMedGoogle Scholar
  • 100 Peragallo JH, Velez FG, Demer JL, Pineles SL. Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis. J Neuroophthalmol 2013; 33 (01) 40-44
    CrossrefPubMedGoogle Scholar
  • 101 Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001; 11 (02) 208-216
    CrossrefPubMedGoogle Scholar
  • 102 Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. Ophthalmology 1996; 103 (04) 623-630
    CrossrefPubMedGoogle Scholar
  • 103 Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014; 21 (05) 687-693
    CrossrefPubMedGoogle Scholar
  • 104 Sanders DB, Wolfe GI, Benatar M. , et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87 (04) 419-425
    CrossrefPubMedGoogle Scholar
  • 105 Palace J, Newsom-Davis J, Lecky B. ; Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50 (06) 1778-1783
    CrossrefPubMedGoogle Scholar
  • 106 Pedersen EG, Pottegård A, Hallas J. , et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol 2014; 21 (03) 454-458
    CrossrefPubMedGoogle Scholar
  • 107 Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol 2008; 255 (04) 510-513
    CrossrefPubMedGoogle Scholar
  • 108 Sanders DB, Hart IK, Mantegazza R. , et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71 (06) 400-406
    CrossrefPubMedGoogle Scholar
  • 109 Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11: 97
    CrossrefPubMedGoogle Scholar
  • 110 Gilhus NE. Eculizumab: a treatment option for myasthenia gravis?. Lancet Neurol 2017; 16 (12) 947-948
    CrossrefPubMedGoogle Scholar
  • 111 Wolfe GI, Kaminski HJ, Aban IB. , et al; MGTX Study Group. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016; 375 (06) 511-522 (Erratum in: Randomized Trial of Thymectomy in Myasthenia Gravis. [N Engl J Med 2017])
    CrossrefPubMedGoogle Scholar
  • 112 Wolfe GI, Kaminski HJ, Aban IB. , et al; MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 2019; 18 (03) 259-268
    CrossrefPubMedGoogle Scholar
  • 113 Gilbert ME, De Sousa EA, Savino PJ. Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy. Arch Neurol 2007; 64 (12) 1790-1792
    CrossrefPubMedGoogle Scholar
  • 114 Chavis PS, Stickler DE, Walker A. Immunosuppressive or surgical treatment for ocular myasthenia gravis. Arch Neurol 2007; 64 (12) 1792-1794
    CrossrefPubMedGoogle Scholar
  • 115 Roberts PF, Venuta F, Rendina E. , et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001; 122 (03) 562-568
    CrossrefPubMedGoogle Scholar
  • 116 Liu Z, Feng H, Yeung SC. , et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 2011; 92 (06) 1993-1999
    CrossrefPubMedGoogle Scholar
  • 117 Zhu K, Li J, Huang X. , et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci 2017; 38 (10) 1753-1760
    CrossrefPubMedGoogle Scholar
  • 118 Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52 (10) 1121-1127
    CrossrefPubMedGoogle Scholar
  • 119 Wong SH, Plant GT, Cornblath W. Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients?. J Neuroophthalmol 2016; 36 (01) 98-102
    CrossrefPubMedGoogle Scholar
  • 120 Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 1995; 119 (06) 792-795
    CrossrefPubMedGoogle Scholar
  • 121 Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye (Lond) 2005; 19 (03) 258-263
    CrossrefPubMedGoogle Scholar
  • 122 Butler IJ, Gadoth N. Kearns-Sayre syndrome. A review of a multisystem disorder of children and young adults. Arch Intern Med 1976; 136 (11) 1290-1293
    CrossrefPubMedGoogle Scholar
  • 123 Emery AE. The muscular dystrophies. Lancet 2002; 359 (9307): 687-695
    CrossrefPubMedGoogle Scholar
  • 124 Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005; 32 (01) 1-18
    CrossrefPubMedGoogle Scholar
  • 125 Garg N, Yiannikas C, Hardy TA. , et al. Late presentations of congenital myasthenic syndromes: How many do we miss?. Muscle Nerve 2016; 54 (04) 721-727
    CrossrefPubMedGoogle Scholar
  • 126 North KN, Wang CH, Clarke N. , et al; International Standard of Care Committee for Congenital Myopathies. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord 2014; 24 (02) 97-116
    CrossrefPubMedGoogle Scholar
  • 127 Evans BJ. Optometric prescribing in decompensated heterophoria. Optometry in Practice 2008; 9: 63-78
    PubMedGoogle Scholar
  • 128 Arnoldi K, Reynolds JD. A review of convergence insufficiency: what are we really accomplishing with exercises?. Am Orthopt J 2007; 57: 123-130
    CrossrefPubMedGoogle Scholar
  • 129 Engel AG. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes. J Neurol Neurosurg Psychiatry 1980; 43 (07) 577-589
    CrossrefPubMedGoogle Scholar